Loading stock data…
PFE
$26.70+0.44 (+1.68%)
Pre-Market$26.77+0.07 (+0.26%)· Last close Apr 30
Pfizer Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pfizer Inc. in the Healthcare sector is trading at $26.70. The stock is currently 7% below its 52-week high of $28.75, remaining 5.9% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why PFE maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHABBV
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.70
Potential Upside
4%
Whystock Fair Value$27.76
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$29.00+8.6%
Range$24.00 – $36.00
Fundamentals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$152.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.71
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Strong income play. Yield provides a meaningful total return floor.
630.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.43%
Volume
Today's trading volume
39.03M
Recent News
Is Pfizer (PFE) Pricing Its Long Term Cash Flow Potential Fairly Today
If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share performance gives you a useful starting point. At a last close of US$26.70, the stock has moved 0.1% over the past week, dipped 4.9% over the last 30 days, is up 6.0% year to date, and has risen 19.7% over the past year, with 3 year and 5 year returns of 16.3% and 13.4% declines respectively. Recent headlines around Pfizer have focused on its broader position in...
Morgan Stanley Maintains Pfizer (PFE) at Equal Weight, Highlights Patent Concerns
Pfizer Inc. (NYSE:PFE) is included among the 10 Innovative Dividend Stocks to Buy Right Now. On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on the stock. The firm said that Pfizer has reached a settlement with all three Vyndamax generic filers. The […]
Pfizer (PFE) Among Best Medical Stocks Under $30 to Invest In?
Pfizer Inc. (NYSE:PFE) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, together with Astellas Pharma Inc., that the US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for Priority Review. The application is for the use of PADCEV (enfortumab vedotin-ejfv) […]
Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%
Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.
Pfizer Just Scored a Win That Wall Street Can't Ignore
The pharmaceutical giant just extended the lifespan of one of its top drugs.